Dataset Information


Baseline Naive CD4+ T-cell Level Predicting Immune Reconstitution in Treated HIV-infected Late Presenters.



Among HIV-infected patients initiating antiretroviral therapy (ART), early changes in CD4+ T-cell subsets are well described. However, HIV-infected late presenters initiating treatment present with a suboptimal CD4+ T-cell reconstitution and remain at a higher risk for AIDS and non-AIDS events. Therefore, factors associated with CD4+ T-cell reconstitution need to be determined in this population, which will allow designing effective immunotherapeutic strategies.


Thirty-one adult patients with baseline CD4+ T-cell count <350 cells/mm3 exhibiting viral suppression after ART initiation were followed in the HIV/AIDS research center of Peking Union Medical College Hospital in Beijing, China, from October 2002 to September 2013. Changes in T-cell subsets and associated determinants were measured.


Median baseline CD4+ T-cell count was 70 cells/mm3. We found a biphasic reconstitution of T-cell subsets and immune activation: a rapid change during the first 6 months followed by a more gradual change over the subsequent 8 years. Baseline CD4+ T-cell count >200 cells/mm3 in comparison to CD4+ T-cell count ?200 cells/mm3 was associated with more complete immune Reconstitution (77.8% vs. 27.3% respectively; P = 0.017) and normalized CD4/CD8 ratio. We showed that the baseline percentage of naive CD4+ T-cell was a predictive marker for complete immune reconstitution (area under receiver operating characteristic curve 0.907), and 12.4% as cutoff value had a sensitivity of 84.6% and a specificity of 88.2%.


Baseline naive CD4+ T-cell percentage may serve as a predictive marker for optimal immune reconstitution during long-term therapy. Such study findings suggest that increasing thymic output should represent an avenue to improve patients who are diagnosed late in the course of infection.


PROVIDER: S-EPMC5126159 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC5055355 | BioStudies
2018-01-01 | S-EPMC5790272 | BioStudies
2014-01-01 | S-EPMC4016205 | BioStudies
2012-01-01 | S-EPMC3371025 | BioStudies
2019-01-01 | S-EPMC6712592 | BioStudies
2020-01-01 | S-EPMC6960461 | BioStudies
2019-01-01 | S-EPMC6377778 | BioStudies
2015-01-01 | S-EPMC4368570 | BioStudies
2020-01-01 | S-EPMC7050791 | BioStudies
2020-01-01 | S-EPMC7507109 | BioStudies